Axsome Therapeutics Earnings Estimate
| AXSM Stock | USD 184.74 1.44 0.79% |
Axsome Therapeutics Revenue Breakdown by Earning Segment
By analyzing Axsome Therapeutics' earnings estimates, investors can diagnose different trends across Axsome Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. As of the 18th of February 2026, Gross Profit is likely to grow to about 425.5 M, while Pretax Profit Margin is likely to drop (0.70). Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Axsome Therapeutics Earnings Estimation Breakdown
The calculation of Axsome Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Axsome Therapeutics is estimated to be 0.08615 with the future projection ranging from a low of -0.9075 to a high of 1.2475. Please be aware that this consensus of annual earnings estimates for Axsome Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.91 Lowest | Expected EPS | 1.25 Highest |
Axsome Therapeutics Earnings Projection Consensus
Suppose the current estimates of Axsome Therapeutics' value are higher than the current market price of the Axsome Therapeutics stock. In this case, investors may conclude that Axsome Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Axsome Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 20 | 75.71% | 0.0 | 0.08615 | -4.68 |
Axsome Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Axsome Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Axsome Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Axsome Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Axsome Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Axsome Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Axsome Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Axsome Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Axsome Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-03 | 2025-09-30 | -0.85 | -0.95 | -0.1 | 11 | ||
2025-08-04 | 2025-06-30 | -1.06 | -0.97 | 0.09 | 8 | ||
2025-05-05 | 2025-03-31 | -1.21 | -1.2157 | -0.0057 | 0 | ||
2025-02-18 | 2024-12-31 | -1.0026 | -1.54 | -0.5374 | 53 | ||
2024-11-12 | 2024-09-30 | -1.41 | -1.3419 | 0.0681 | 4 | ||
2024-08-05 | 2024-06-30 | -1.33 | -1.67 | -0.34 | 25 | ||
2024-05-06 | 2024-03-31 | -1.2 | -1.44 | -0.24 | 20 | ||
2024-02-20 | 2023-12-31 | -1.17 | -2.08 | -0.91 | 77 | ||
2023-11-06 | 2023-09-30 | -1.2 | -1.32 | -0.12 | 10 | ||
2023-08-07 | 2023-06-30 | -1.22 | -1.54 | -0.32 | 26 | ||
2023-05-08 | 2023-03-31 | -1.04 | -0.26 | 0.78 | 75 | ||
2023-02-27 | 2022-12-31 | -1.14 | -1.41 | -0.27 | 23 | ||
2022-11-07 | 2022-09-30 | -1.08 | -1.07 | 0.01 | 0 | ||
2022-08-09 | 2022-06-30 | -1.21 | -1.06 | 0.15 | 12 | ||
2022-05-02 | 2022-03-31 | -1 | -1.03 | -0.03 | 3 | ||
2022-03-01 | 2021-12-31 | -1.02 | -0.9 | 0.12 | 11 | ||
2021-11-08 | 2021-09-30 | -0.95 | -0.93 | 0.02 | 2 | ||
2021-08-09 | 2021-06-30 | -0.96 | -0.86 | 0.1 | 10 | ||
2021-05-10 | 2021-03-31 | -0.87 | -0.78 | 0.09 | 10 | ||
2021-03-01 | 2020-12-31 | -0.76 | -0.78 | -0.02 | 2 | ||
2020-11-05 | 2020-09-30 | -0.57 | -0.58 | -0.01 | 1 | ||
2020-08-10 | 2020-06-30 | -0.62 | -0.49 | 0.13 | 20 | ||
2020-05-08 | 2020-03-31 | -0.62 | -0.88 | -0.26 | 41 | ||
2020-03-12 | 2019-12-31 | -0.48 | -0.71 | -0.23 | 47 | ||
2019-11-07 | 2019-09-30 | -0.4 | -0.56 | -0.16 | 40 | ||
2019-08-08 | 2019-06-30 | -0.33 | -0.41 | -0.08 | 24 | ||
2019-05-09 | 2019-03-31 | -0.3 | -0.32 | -0.02 | 6 | ||
2019-03-14 | 2018-12-31 | -0.3 | -0.32 | -0.02 | 6 | ||
2018-11-09 | 2018-09-30 | -0.29 | -0.31 | -0.02 | 6 | ||
2018-08-08 | 2018-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2018-05-08 | 2018-03-31 | -0.28 | -0.19 | 0.09 | 32 | ||
2018-03-07 | 2017-12-31 | -0.31 | -0.31 | 0.0 | 0 | ||
2017-11-08 | 2017-09-30 | -0.34 | -0.27 | 0.07 | 20 | ||
2017-08-09 | 2017-06-30 | -0.34 | -0.3 | 0.04 | 11 | ||
2017-05-09 | 2017-03-31 | -0.39 | -0.41 | -0.02 | 5 | ||
2017-03-07 | 2016-12-31 | -0.42 | -0.4 | 0.02 | 4 | ||
2016-11-14 | 2016-09-30 | -0.39 | -0.38 | 0.01 | 2 | ||
2016-08-09 | 2016-06-30 | -0.39 | -0.36 | 0.03 | 7 | ||
2016-05-11 | 2016-03-31 | -0.28 | -0.31 | -0.03 | 10 | ||
2016-03-24 | 2015-12-31 | -0.22 | -0.12 | 0.1 | 45 |
About Axsome Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Axsome Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Axsome Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Axsome Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -1 B | -960 M | |
| Retained Earnings Total Equity | -368.3 M | -349.9 M | |
| Earnings Yield | (0.06) | (0.07) | |
| Price Earnings Ratio | (12.70) | (13.34) | |
| Price Earnings To Growth Ratio | (1.19) | (1.13) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.68) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.